The deal de-risks early-stage development of a novel mRNA degrader without diluting ORIC's balance sheet. Watch for CTA filing and Phase 1 initiation timelines; the option structure gives ORIC flexibility to reacquire a derisked asset after Phase 1/2 data.
Price Chart
Executive Summary
ORIC Pharmaceuticals announced a partnership with Cancer Research UK to fully fund and execute CTA-enabling studies and Phase 1/2 clinical development of ORIC-259, a potential first-in-class CIP2A mRNA degrader for HRD cancers. ORIC retains an option to reacquire rights after Phase 1/2 data, with CRUK eligible for downstream milestones and royalties. This structure preserves ORIC's cash while advancing a novel preclinical asset into the clinic.
Key Facts
- Cancer Research UK will fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development of ORIC-259.
- ORIC retains an exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data.
- Cancer Research UK is eligible to receive downstream milestone payments and royalties.
- ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target.
- Preclinical data show robust antitumor activity in PARP inhibitor sensitive and resistant settings.
- ORIC's clinical pipeline includes rinzimetostat (EED inhibitor for prostate cancer) and enozertinib (EGFR exon20/NSCLC).
Financial Impact
No upfront or near-term financial terms disclosed; CRUK fully funds development through Phase 1/2. ORIC retains option to reacquire, with CRUK eligible for milestones and royalties.
Risk Factors
- ORIC-259 is preclinical; no clinical data yet and CTA-enabling studies have not started.
- ORIC's option to reacquire is contingent on Phase 1/2 data; if data are negative, the program may be abandoned.
- CIP2A is a novel target; clinical proof-of-concept is unproven.
- No financial terms disclosed; CRUK's milestone/royalty structure could reduce ORIC's future economics if the option is exercised.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374985 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $13.17 $8.96 | ▼ −32.00% | ▼ −32.72% | $9.00 (−31.66%) |
Oct 5, 2026 22d ago | Press Release | $11.98 $12.01 | ▲ +0.25% | ▲ +0.49% | $9.00 (−24.87%) |
Oct 2, 2026 25d ago | Insider Cluster | $12.49 $11.98 | ▼ −4.08% | ▼ −4.63% | $9.00 (−27.94%) |
Aug 3, 2026 12w ago | Press Release | $13.47 $12.93 | ▼ −4.01% | ▼ −3.81% | $9.00 (−33.18%) |
Jun 22, 2026 18w ago | 8-K | $8.91 $9.43 | ▲ +5.84% | ▲ +5.88% | $9.00 (+1.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $7.82 $8.27 | ▲ +5.75% | ▲ +5.21% | $9.00 (+15.09%) |
May 4, 2026 25w ago | 8-K | $9.57 $9.57 | · 0.00% | ▼ −1.38% | $9.00 (−5.96%) |
Apr 3, 2026 29w ago | Press Release | $8.91 $8.87 | ▼ −0.45% | ▼ −0.51% | $9.00 (+1.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers